Bildkälla: Stockfoto

Biosergen Q2 2023: Stable in costs but delays in clinical timeline - Carlsquare

Carlsquare Equity Research has published a research update following the Q2 2023 report.

Carlsquare Equity Research has published a research update following the Q2 2023 report.
Börsvärldens nyhetsbrev
ANNONSER